Detalles de la búsqueda
1.
The Impact of Nutritional Support on Survival Outcomes in Patients with Advanced Gastric Adenocarcinoma Treated with Chemotherapy.
Nutr Cancer
; 75(3): 867-875, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36591915
2.
Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study.
Gastric Cancer
; 26(6): 1020-1029, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37610558
3.
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
Cancer Immunol Immunother
; 71(11): 2743-2755, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35429246
4.
Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial.
BMC Cancer
; 22(1): 711, 2022 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35765021
5.
Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07.
Gastric Cancer
; 25(1): 188-196, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34351555
6.
Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
Int J Clin Oncol
; 24(7): 836-841, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30778794
7.
The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Ann Surg Oncol
; 24(2): 546-553, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27638675
8.
Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial.
Cancer Med
; 12(15): 16649-16660, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37325934
9.
TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis.
Am J Case Rep
; 23: e936455, 2022 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35700150
10.
Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Ann Surg Oncol
; 23(Suppl 5): 1064, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27646021
11.
Total pancreatectomy with segmental duodenectomy preserving right gastroepiploic vein.
Hepatogastroenterology
; 58(105): 198-201, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21510314
12.
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09.
Target Oncol
; 16(6): 753-760, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34718946
13.
Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study).
Cancer Chemother Pharmacol
; 87(5): 665-672, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33555359
14.
RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer.
JCO Precis Oncol
; 4: 898-911, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35050760
15.
Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Cancer Med
; 9(24): 9419-9430, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33222406
16.
Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan.
Transl Oncol
; 13(7): 100786, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32428838
17.
Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Cancer Med
; 9(5): 1779-1789, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31962002
18.
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
Cancer Chemother Pharmacol
; 81(5): 829-838, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29508026
19.
The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C).
J Cancer
; 9(10): 1725-1730, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29805697
20.
A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.
Cancer Med
; 7(9): 4217-4227, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30051609